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Aims: The purposes of this investigation were 1) to replicate or improve upon the findings of the 
initial study of the Daniel Fast, while 2) maintaining or improving high-density lipoprotein 
cholesterol (HDL-C) via krill oil supplementation.     
Methods: 39 subjects (12 men and 27 women) completed a 21-day Daniel Fast.  During the 
fasting period, 19 subjects were randomly assigned to consume krill oil (2 grams per day in 
capsules), while the other 20 subjects consumed placebo capsules.  Blood samples were collected 
immediately prior to and following the fast and assayed for blood lipids and malondialdehyde. 
Results: Krill oil supplementation had no effect on blood lipids or malondialdehyde (p > 0.05).  
Total cholesterol, HDL-C, and low-density lipoprotein cholesterol each decreased significantly 
from pre to post fast (p < 0.05).  
Conclusion: Although the findings of the initial Daniel Fast study were largely replicated, krill 
oil supplementation does not further improve the blood lipid profile or result in a decrease in 
malondialdehyde.  














This thesis was written in article format for submission to The American Journal of Clinical 
Nutrition following defense.  The content and organization of this thesis represent and fulfill the 
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INTRODUCTION                                                      
Hundreds of scientific investigations have examined the health-related benefits of fasting.  
The fasts featured in these studies can be divided into two broad groups: those that restrict 
energy intake but do not restrict food choices, and vice-versa.  Within the latter group, a 
religiously-motivated fast that has only recently been scientifically examined (1, 2) is the 
Biblically-based Daniel Fast.  This fast proscribes the intake of animal products, refined foods, 
white flour, preservatives, additives, sweeteners, flavorings, caffeine, and alcohol.  
Consequently, only fruits, vegetables, whole grains, nuts, seeds, and oil are allowed during the 
Daniel Fast; although energy intake is unrestricted.     
The initial investigation of a 21-day Daniel Fast noted favorable changes in a variety of 
health-related biomarkers (1, 2).  Specifically, systolic and diastolic blood pressure (BP), total 
cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), hydrogen peroxide, and 
malondialdehyde (MDA) each decreased from pre to post fast, while Trolox Equivalent 
Antioxidant Capacity and nitrate/nitrite both increased.  Also, C-reactive protein, serum insulin, 
and the homeostatic model of insulin resistance were each lowered to a clinically meaningful, 
albeit statistically insignificant, extent.  Unfortunately, this investigation also noted a 14% 
reduction (55.65 ± 2.50 vs. 47.58 ± 2.19 mg·dL
-1
) in high-density lipoprotein cholesterol (HDL-
C) (1).   
High-density lipoprotein cholesterol protects against cardiovascular disease mainly via its 
role in reverse cholesterol transport.  Through this process, HDL-C travels throughout the 
bloodstream and gathers cholesterol from areas of overabundance, including atherogenic foam 
cells (3).  High-density lipoprotein cholesterol then transports this cholesterol to the liver, where 





HDL-C helps protect against inflammation, LDL oxidation, and thrombosis (4).  Also, HDL-C 
increases nitric oxide production and inhibits the expression and migration of atherosclerotic 
adhesion molecules (3).  Given that a 1 mg·dL
-1
 increase in HDL-C lowers the risk of developing 
cardiovascular disease by 2% and 3% in men and women, respectively (5), a 14% reduction in 
this lipoprotein is not ideal if the Daniel Fast is to be regarded as a dietary regimen that promotes 
optimal cardiovascular health.   
Theoretically, including an intervention known to raise HDL-C could counterbalance a 
fast-induced lowering of this lipoprotein.  Three interventions that have been scientifically 
demonstrated to increase HDL-C are the performance of regular exercise, the use of prescription 
drugs, and the intake of selected nutrients.  A recent meta-analysis found that aerobic exercise 
training increases HDL-C by an average of 2.53 mg·dL
-1
 (6), which is insufficient to offset an 
8.07 mg·dL
-1
 decrease that was reported in the initial study of the Daniel Fast (1).  Moreover, 
although several pharmaceuticals (statins, niacin, fibrates, thiazolidnediones, glitazars, 
cholesteryl ester transfer protein inhibitors, and recombinant HDL infusion) have been shown to 
substantially raise HDL-C (3), use of these drugs without a medical need departs from the 
abstemious philosophy of a Daniel Fast.  All-natural dietary components or nutritional 
supplements, on the other hand, appear to be ideal intervention candidates. 
A promising candidate in this regard is krill oil.  This unique oil, which is extracted from 
Antarctic krill, is abundant in docosahexaenoic acid and eicosapentaenoic acid (7).  Unlike most 
fish oils, krill oil carries the majority of these acids in a phospholipid form, which allows for 
better intestinal absorption and more rapid incorporation into cell membranes (7, 8).  Moreover, 
krill oil contains astaxanthin, a potent antioxidant that has been shown to protect rats (9) and 





supplementation at a dosage of 1-3 g·d
-1
 for 90 days was reported to decrease TC between 13-
18% and LDL-C between 32-39% (11).  The same investigation reported that HDL-C increased 
between 43-60% following krill oil supplementation.      
However, two recent studies (12, 13) found that krill oil supplementation (1 g·d
-1
 for 42 
days and 3 g·d
-1
 for 49 days, respectively) had no effect on HDL-C.  These two studies also 
found that krill oil supplementation had little (12) to no effect (13) on biomarkers of lipid 
peroxidation, which runs counter to findings that astaxanthin attenuates this type of oxidative 
stress (14). 
The heterogeneity of findings pertaining to krill oil’s effects on blood lipids and lipid 
peroxidation provide an impetus for further investigation.  Thus, the main purposes of the present 
study were 1) to attempt to replicate or improve upon (via krill oil supplementation) the findings 
of the initial study of a 21-day Daniel Fast in terms of improving the blood lipid profile and 
lowering MDA; and 2) to determine if HDL-C can be maintained or even improved during a 21-
day Daniel Fast via krill oil supplementation.   
 
SUBJECTS AND METHODS 
Subjects and Screening 
 40 subjects (12 men and 28 women) were initially enrolled in this study.  1 subject 
withdrew from the study due to illness and a family emergency.  The subjects had a mean age of 
34 ± 2 years, with a range of 19-65 years.  6 subjects had elevated BP upon screening (≥140/90 
mmHg), seven subjects had elevated TC (>200 mg∙dL
-1
), and 2 were diabetic (type 2).  One man 
used a statin, and one used a benign prostatic hyperplasia medication.  One woman used a statin, 





used oral contraceptives, two used hormone replacement therapy, one used a stimulant/appetite 
suppressant, one used an antibiotic, one used insulin, one used a sleep aid, one used migraine 
medication, one used acne medication, one used hyperthyroid medication, and two used 
hypothyroid medication.  All subjects were nonsmokers and were not consuming antioxidant 
supplements from two weeks prior to commencing the Daniel Fast until the conclusion of the 
fast.  Subjects’ baseline characteristics are presented in Table 1.  
As with our initial investigation, no restrictions were placed on subjects regarding body 
mass index (BMI) necessary for enrollment.  This was due to the fact that individuals in all 
weight categories, regardless of body mass at entry, responded well to the fast (1, 2).  Therefore, 
the BMI of subjects ranged from 18 kg∙m
-2
 to 37 kg∙m
-2
; with 22 subjects classified as normal 
weight (BMI <25 kg∙m
-2
), 9 classified as overweight (BMI 25-29.9 kg∙m
-2
), and 8 classified as 
obese (BMI ≥30 kg∙m
-2
).  Of the 39 subjects that completed the investigation, 33 were classified 
as exercise-trained (defined as performing a combined minimum of 2 hours per week of 
anaerobic and aerobic exercise of moderate to high intensity).  Specifically, subjects performed 
2.1±0.2 hours of anaerobic and 4.7±0.4 hours of aerobic exercise per week for the past 6.8±1.1 
and 8.3±1.0 years, respectively.  Eligibility and classification were determined via completion of 
questionnaires pertaining to health history, physical activity, and drug and dietary supplement 
usage.  Prior to participation, each subject was informed of all procedures, potential risks, and 
benefits associated with the study in both verbal and written form in accordance with the 
approved procedures of the University Institutional Review Board for Human Subjects Research 
(H11-14).  Subjects signed an informed consent form prior to being admitted as a subject.  
During the initial visit to the laboratory, subjects completed all paperwork, were provided 





reviewed food models in order to improve the accuracy of recording (as described below), and 
were provided a calendar outlining their full participation.  Subjects were also provided a 
detailed outline of foods that are allowed as well as commonly consumed foods that are not 
allowed.  A recipe guide was also provided.  It should be noted that subjects purchased and 
prepared all of their food.  Subjects returned to the laboratory 1-2 weeks later to have baseline 
assessments performed and to begin the 21-day fast.  The outcome variables described below 
were measured before (baseline: day 1 of the fast) and after the fast (day 22).  All data collection 
was done in the morning hours (5:00-11:00 am) while subjects were in a 12-hour post-absorptive 
state. 
Heart Rate and Blood Pressure 
 Upon arrival at the laboratory, subjects were asked to void.  Women performed a urine 
pregnancy test to confirm that they were not pregnant, as pregnant women were not allowed to 
participate in this study due to potential fetal radiation exposure during a dual energy x-ray 
absorptiometry (DEXA) scan.  Subjects were then seated in a chair with a blood pressure cuff 
placed on their left arm.  After resting for 10 minutes, subjects’ heart rate was measured via 
palpation for 60 seconds using the radial artery by two trained technicians – one on each wrist.  
Blood pressure was then measured via auscultation using a calibrated manometer and a dual 
earpiece stethoscope that allowed two technicians to listen simultaneously.  The average of all 
measures was used in data analysis.  If values deviated by more than 5 beats per minute for heart 
rate or 5 mmHg for blood pressure, an additional measure was taken and the two closest 








 Subjects’ height was measured using a stadiometer, and body weight was measured using 
a calibrated medical scale.  Body mass index was calculated as weight (kg) divided by height 
squared (m
2
).  Waist and hip circumference measurements were obtained using a tension-
regulated measuring tape, with subjects wearing “spandex-like” shorts.  Body composition was 
determined via DEXA (Hologic QDR-4500W) using a 4-minute fan array.  Specifically, total 
and regional (trunk-specific) body fat was measured.  The assessment was performed by a 
licensed technician. 
Blood Collection and Biochemical Variables 
Venous blood samples were taken from subjects’ antecubital vein via needle and 
Vacutainer™ by a trained phlebotomist.  Following collection, the blood samples were processed 
accordingly, and a portion of the plasma/serum were sent to Laboratory Corporation of America 
(LabCorp) for analysis of the lipid panel using enzymatic procedures (Roche/Hitachi Modular).  
The remaining blood samples were stored at -70°C until they were analyzed for MDA following 
the procedures of Jentzsch et al. (15) using reagents purchased from Northwest Life Science 
Specialties (Vancouver, WA).  Specifically, 75µL of plasma was added to microcentrifuge 
reaction tubes with the addition of 3µL of butylated hydroxytoluene in methanol to minimize ex 
vivo lipid peroxidation.  75µL of 1M phosphoric acid and 75µL of 2-thiobarbituric acid reagent 
were added to each reaction tube and mixed thoroughly.  Samples and reagents were incubated 
for 60 minutes at 60°C.  Following incubation, tubes were removed, and the reaction mixture 
was transferred to a microplate.  The absorbance was read using a spectrophotometer at both 535 
and 572nm to correct for baseline absorption.  Malondialdehyde equivalents were calculated 





calibration curve using tetramethoxypropane in a stabilizing buffer.  The detection limit for 
MDA, as per the manufacturer, is 0.1µM.  
Conditions (Supplementation) 
 On a double-blind basis, subjects were randomly assigned to consume one of the 
following for the entire duration of the 21-day fast: 1) 19 subjects consumed krill oil capsules 
(NOW Foods, Bloomingdale, IL: 2 grams per day in two daily dosages of 1 gram); and 2) twenty 
subjects consumed placebo capsules (coconut oil; NOW Foods, Bloomingdale, IL: 2 grams per 
day in two daily dosages of 1 gram).  Specifically, half of the male subjects and half of the 
female subjects were placed in the group supplementing with krill oil, and the remaining subjects 
were placed in the group supplementing with a placebo.  The krill oil provided approximately 2-
3 mg·d
-1
 of esterified astaxanthin.  Subjects were instructed to consume one capsule in the 
morning (with breakfast) and one capsule in the evening (with dinner) every day for the 21-day 
period.  For both conditions, capsule counts upon bottle return determined compliance to the 
supplementation.   
Dietary Records and Physical Activity                                                                                                    
Dietary Records and Physical Activity                                                                                                                                      
 All subjects were instructed to maintain their normal diet until they began the fast and to 
record on food logs all food and beverage consumed during the 7 days immediately prior to the 
start of the fast.  Subjects were also instructed to record food and beverage intake during the final 
seven days of the fast.  A technician reviewed in detail the food logs with each subject upon 
receipt.  Records were analyzed by using Food Processor SQL, version 9.9 (ESHA Research, 
Salem, OR).  Regarding physical activity, subjects were instructed to maintain their normal 
habits during the entire study period with one notable exception: subjects were instructed not to 





Subjects were also instructed to refrain from alcohol consumption during the fast, as well as 
during the 48 hours that preceded day 1. 
Post-Fast Questionnaire 
 During their final visit to the laboratory, subjects completed a questionnaire pertaining to 
their experience with the fast.  Subjects rated their compliance to the fast, their overall physical 
health/vitality during the fast, their overall mental mood during the fast, and their overall satiety 
during the fast.  
Statistical Analysis 
All outcome measures were analyzed using a 2 (condition) x 2 (pre/post fast) analysis of 
variance.  However, data for both conditions were subsequently collapsed and analyzed using a 
paired t-test.  Analyses were performed using JMP statistical software (version 4.0.3, SAS 
Institute, Cary, NC).  Statistical significance was set at P ≤ 0.05.  The data are presented as mean 
± SEM.  
 
RESULTS 
 The outcome measures of main interest in the present study were blood lipids and MDA.  
Although we hypothesized that these values would improve to a greater extent in subjects 
supplementing with krill oil, this was not confirmed by our statistical analyses.  In fact, subjects 
in the krill oil and placebo groups had nearly identical pre- and post-fast blood lipid and MDA 
values.  A summary of our findings is presented in Table 2.  Based on these analyses, data for 
all variables were pooled and are simply presented as pre and post fast.  As such, all data were 






Compliance, Mood, and Satiety 
Thirty-nine subjects (12 men and 27 women) completed the 21-day fast as well as the 
pre- and post-fast assessments.  Compliance to the fast was 97.8 ± 0.4%.  On a scale from 0-10, 
subjects rated their “physical feeling of health and vitality” (8.3 ± 0.2), “mental outlook and 
mood” (8.6 ± 0.2), and “level of satiety” (8.0 ± 0.2) during the fast.    
Body Weight and Body Fat  
Although not a main outcome measure, we recorded both bodyweight and body fat 
percentage pre and post intervention.  Bodyweight was significantly (p < 0.0001) lower post fast 
(71.53 kg) compared to pre fast (74.14 kg).  Body fat percentage was also significantly (p = 
0.0028) lower post fast (28.80%) compared to pre fast (29.39%).  
Blood Lipids and Malondialdehyde 
 Significant (p < 0.05) reductions from pre to post fast were noted in several parameters of 
the lipid panel, which can be viewed in Table 3.  Malondialdehyde did not change to a 
significant extent (p = 0.79; Table 3).  
Dietary Data 
Several differences existed in dietary intake from pre fast to the final week of the fast. 
These included decreases in total kilocalories (p < 0.01), protein grams (p < 0.01), the percentage 
of protein (p < 0.01), fat grams (p = 0.02), saturated fatty acid (SFA) (p < 0.01), trans fat (p < 
0.01), and cholesterol (p < 0.01).  Increases in the percent of carbohydrate intake (p < 0.01), fiber 
(p < 0.01), polyunsaturated fatty acid (PUFA) (p = 0.01), vitamin C (p < 0.01), vitamin E (p = 








 Although the initial investigation of the Daniel Fast reported favorable changes in many 
health-related biomarkers, a 14% decrease in HDL-C was also noted (1).  Thus, the main purpose 
of the present investigation was to determine if krill oil supplementation at 2 g·d
-1
 for 21 days 
would maintain or even increase HDL-C in individuals partaking in a 21-day Daniel Fast.  
Unfortunately, as indicated in Table 2, krill oil supplementation had no effect on HDL-C, which 
decreased by an average of approximately 9% from pre to post fast.  This finding strongly 
contradicts the 55% increase in HDL-C following supplementation of krill oil at 2 g·d
-1
 for 90 
days that was reported by Bunea and colleagues (11).  Rather, our findings are more similar to 
those of two recent investigations.  Skarpańska et al. (12) and Ulven et al. (13) both reported that 
krill oil supplementation (1 g·d
-1
 for 42 days and 3 g·d
-1
 for 49 days, respectively) had no effect 
on HDL-C.    
 In addition to its lack of effect on HDL-C, krill oil supplementation failed to affect any 
other blood lipid (Table 2).  Again, our findings oppose those of Bunea and coworkers (11) but 
support those of Skarpańska et al. (12) and Ulven et al. (13).  Bunea and coworkers (11) reported 
that krill oil supplementation at the aforementioned dosage and duration decreased TC, LDL-C, 
and triglycerides (TAG) by 18%, 37%, and 28%, respectively.  In contrast, Skarpańska et al. (12) 
and Ulven et al. (13) both reported that krill oil supplementation at the aforementioned dosages 
and durations had no effect on TC, LDL-C, or TAG.   
 Two features in the study design of Bunea et al. (11) markedly differed from the designs 
of the other investigations that examined the effects of krill oil supplementation on human blood 
lipids.  First, the 90-day krill oil supplementation period of Bunea et al. (11) was considerably 





periods of the other investigations.  Second, pre-supplementation TC, LDL-C, and TAG were 
each substantially higher in the study conducted by Bunea et al. (11) compared to the other 
studies (Table 5). Clearly, individuals that have the greatest ”room for improvement” and are 
supplementing for the longest duration are likely to experience the most robust changes in their 
blood lipid profile.    
 However, pre-supplementation HDL-C was similar across the studies: 58.0 mg·dL
-1
 in the 
study conducted by Ulven et al. (13), 61.0 mg·dL
-1
 in the study conducted by Skarpańska et al. 
(12), 55.97 mg·dL
-1
 in the present study, and 57.22 mg·dL
-1
 in subjects supplementing with krill 
oil at 1.0 g·d
-1
 (who experienced a 43.92% increase in this cholesterol following 
supplementation) in the study conducted by Bunea et al. (11).  Thus, other than the longer 
supplementation duration, it is unclear why Bunea and colleagues (11) found such a dramatic 
increase in HDL-C compared to the other investigations. 
 We hypothesized that krill oil supplementation would reduce MDA due to its astaxanthin 
content, as this antioxidant has been shown to attenuate lipid peroxidation in rats (both in vitro 
and in vivo) (9) and human endothelial cells in vitro (10).  However, krill oil supplementation 
had no effect on MDA in the present study, and two recent investigations have reported similar 
findings.  The aforementioned investigation conducted by Ulven et al. (13) found no change in 
the lipid-specific marker F2-Isoprostanes (F2-IsoPs).  The work of Skarpańska et al. (12) found 
that krill oil supplementation reduced the lipid-specific marker, thiobarbituric acid reactive 
substances, 24 hours following the completion of a rowing 2000 meter time trial.  However, krill 
oil supplementation had no effect on thiobarbituric acid reactive substances immediately before 





 Two possible explanations for the lack of effect of krill oil supplementation on MDA are 
worthy of mention.  First, despite being shown to reduce lipid peroxidation in animals and in 
human cells in vitro, astaxanthin could potentially be ineffective at reducing lipid peroxidation in 
humans in vivo.  In fact, a recent investigation found that astaxanthin supplementation at 8 mg·d-1 
for 8 weeks did not affect plasma 8-isoprostane concentrations (16).  Thus, it is possible that the 
2-3 mg·d
-1
 dosage of astaxanthin provided by the krill oil in the present study was insufficient to 
lower MDA.  Alternatively, even if such a dosage were sufficient to reduce MDA, such a 
reduction could be potentially masked by an increase in lipid peroxidation due to the 
eicosapentaenoic acid and docosahexaenoic acid contained in the krill oil.  Specifically, 
integration of these acids into membranes and lipoproteins could increase lipid peroxidation by 
increasing the unsaturation index (17).  Indeed, lipid peroxidation has been found to increase 
following intake of omega 3 fatty acids (18).  However, other investigations have found that 
omega 3 fatty acid consumption decreases (19) or does not affect (20) lipid peroxidation.  
Therefore, more investigations are needed to determine the effects of krill oil supplementation on 
MDA and other biomarkers of lipid peroxidation.      
 Few investigations have compared the effects of krill oil and fish oil on blood lipids and 
lipid peroxidation.  The aforementioned study conducted by Bunea et al. (11)  reported that krill 
oil supplementation elicited superior changes in HDL-C, LDL-C, TC, and TAG compared to fish 
oil supplementation at 3 g·d
-1
 for 90 days.  However, a recent study (13) found no difference in 
HDL-C, LDL-C, TC, TAG, or the HDL-C:TAG ratio between subjects supplementing with krill 
oil at 3 g·d
-1
 for 49 days and subjects supplementing with fish oil at 1.8 g·d
-1
 for the same time 
period.  The same investigation found that neither krill oil supplementation nor fish oil 





 Considering our collapsed data, a 21-day Daniel Fast resulted in reductions in TC, HDL-
C, and LDL-C; while TAG and very low-density lipoprotein cholesterol did not change 
significantly (Table 3).  Similar findings were reported in the initial investigation of the Daniel 
Fast (1).  This is not surprising given that compliance to the fast was similar between studies 
(97.8 ± 0.4% and 98.7 ± 0.2% in the present study and the initial study, respectively).  Both the 
TC:HDL-C ratio and the LDL-C:HDL-C ratio decreased in the present investigation, whereas the 
TC:HDL-C ratio did not change in the initial investigation. (The LDL-C:HDL-C ratio was not 
included.)  Considering that the decrease in TC was similar between studies, differences in the 
TC:HDL-C ratio are mainly due to the fact that HDL-C decreased to a lesser extent in the present 
study compared to the initial study (9% and 14%, respectively). 
 The Daniel Fast complies with nearly all of the dietary recommendations given by the 
Adult Treatment Panel III of the National Cholesterol Education Program for maintaining 
desirable blood lipid values (21), including the recommended intake of SFAs, PUFAs, 
monounsaturated fatty acids (MUFAs), total fat, fiber, protein, and cholesterol (22).  Studies 
featuring dietary intakes similar to these recommendations, particularly those that reduce intake 
of SFAs and cholesterol, have been shown to reduce LDL-C by an average of 16% (23).  This is 
similar to the reductions in LDL-C noted by the initial (1) and present investigation of a 21-day 
Daniel Fast (23% and 20%, respectively). 
It appears that plant-based diets may be superior to diets that include animal products at 
reducing cholesterol concentrations.  Moreover, plant-based diets that restrict animal product 
consumption to the greatest extent result in the largest reductions of TC and LDL-C.  





(allowing eggs, dairy products, and an occasional small quantity of lean meat) decrease TC and 
LDL-C by 10-15%, whereas vegan diets decrease these cholesterols by 15-25% (24). 
However, the most-favorable effects on blood lipids are likely observed in “portfolio” 
diets that emphasize the consumption of viscous fibers, plant sterols, vegetable proteins, and nuts 
(25).  Four metabolically controlled 4-week trials have reported reductions in TC and LDL-C by 
22-27% and 29-35%, respectively (26-29).  When comparing the findings of these investigations 
to the present one, three considerations are worthy of mention: First, subjects in the dietary 
portfolio studies had substantially higher baseline LDL-C than subjects in the present study.  
Second, the dietary intervention was 33% longer in the dietary portfolio investigations than in 
the present one.  Third, whereas the subjects in the present study purchased and prepared all of 
their own food, the subjects in the dietary portfolio studies had all of their food delivered to 
them, making them more likely to comply with their diet.  In fact, subjects who purchased and 
prepared all of their own food in accordance with a self-selected dietary portfolio plan for one 
year experienced more modest reductions in TC (10%) and LDL-C (13%) (30).   
Malondialdehyde remained unchanged in the present study despite an increased intake of 
vitamin C and vitamin E, two antioxidants that have been demonstrated to reduce lipid 
peroxidation (31).  This finding runs counter to the 15% reduction in MDA reported in the initial 
investigation of a 21-day Daniel Fast (2).  An important difference between the two studies that 
may have affected MDA values is that PUFA consumption increased by 37% from pre to post 
fast in the present study (6.7 ± 0.5 vs. 9.2 ± 1.0; p = 0.01) but remained unchanged in the initial 
study (8 ± 1 vs. 9 ± 1; p = 0.47) (2).  PUFAs are more susceptible to peroxidation than MUFAs 
and SFAs (32), and increased consumption of PUFAs has been shown to increase lipid 





increased antioxidant intake, leaving MDA unchanged.  Other investigations featuring plant-
based diets have reported minimal effects on MDA (34, 35). 
The search for a non-pharmacological intervention capable of maintaining HDL-C during 
a 21-day Daniel Fast continues.  Two potential candidates in this regard are phosphatidylinositol 
supplementation and increased MUFA consumption.  Two weeks of phosphatidylinositol 
supplementation at 5.6 g·d
-1
 increased HDL-C by 18% (36).  Unfortunately, this remains the only 
study to date that has examined the effect of phosphatidylinositol supplementation on HDL-C in 
humans.  Jenkins et al. (37) recently reported that substituting 13% of total energy intake as 
carbohydrate with MUFAs (predominantly in the form of sunflower oil) in a portfolio diet for 
four weeks increased HDL-C by 12.5%.  However, it should be noted that subjects in this study 
had much lower baseline HDL-C values (38.7 mg·dL
-1
) than subjects in the present investigation 
(55.97 ± 2.62 mg·dL
-1
).  
       
CONCLUSION 
A 21-day Daniel Fast is associated with reductions in TC, LDL-C, the TC:HDL-C ratio, 
and the LDL-C:HDL-C ratio.  Unfortunately, HDL-C decreased by 9%, and krill oil 
supplementation at 2 g·d
-1
 for 21 days did not prevent this reduction, nor did it impact any other 
cholesterol concentration or MDA.  Future investigations should examine other non-
pharmacological interventions that can potentially maintain HDL-C during the fast, such as 
phosphatidylinositol supplementation or increased MUFA consumption.  Finally, additional 
investigations are needed to compare the effects of krill and fish oil on blood lipids, lipid 
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APPENDIX A – TABLES  
 
 
Table 1. Baseline characteristics of 39 men and women participating in a 21-day Daniel Fast 
 
Variable Value 
Age (yrs) 33.9 ± 2.1 
Height (cm) 168.9 ± 1.4 
Weight (kg)   74.1 ± 2.4 
BMI (kg∙m
-2
)   25.9 ± 0.7 
Waist (cm)   86.8 ± 2.0 
Hip (cm) 101.2 ± 1.8 
Waist:Hip   0.86 ± 0.01 
Body Fat (%)   29.4 ± 1.5 
Heart Rate (bpm)   66.5 ± 1.6 
Systolic Blood Pressure (mmHg) 110.7 ± 2.2 
Diastolic Blood Pressure (mmHg)   71.5 ± 2.3 
Aerobic Exercise (hrs∙wk
-1
)     4.2 ± 0.6 
Years Aerobic Exercise   7.9 ± 1.4 
Anaerobic Exercise (hrs∙wk
-1
)     1.8 ± 0.3 
Years Anaerobic Exercise   5.9 ± 1.4 
 






















Table 2. Probability values for blood lipid and malondialdehyde data for subjects supplementing 
with krill oil and placebo during a 21-day Daniel Fast 
 
Variable Condition Time* Condition x Time 
Cholesterol 0.3855 0.0005 0.9429 
Triglycerides 0.7068 0.2633 0.9007 
HDL-C 0.9253 0.1903 0.5860 
VLDL-C 0.6839 0.2601 0.9612 
LDL-C 0.2471 0.0016 0.7607 
LDL-C:HDL-C 0.1925 0.2290 0.5464 
TC:HDL-C 0.3211 0.3107 0.6112 
MDA 0.8787 0.8709 0.9297 
 
Note: Due to a lack of statistical significance between conditions, data are pooled and presented 
in Table 3.  

































Table 3. Blood lipid and MDA data of 39 men and women before and after a 21-day Daniel Fast 
 
Variable Pre Post P value 
Cholesterol (mg·dL
-1
) 173.07 ± 5.03 146.00 ± 4.82 <0.0001 
Triglycerides (mg·dL
-1
)   82.46 ± 7.40   75.23 ± 5.72 0.18 
HDL-C (mg·dL
-1
)   55.97 ± 2.62   50.90 ± 2.62 <0.0001 
VLDL-C (mg·dL
-1
)   16.54 ± 1.48   15.10 ± 1.14 0.1982 
LDL-C (mg·dL
-1
) 100.56 ± 4.31   80.00 ± 3.66 <0.0001 
LDL-C:HDL-C     1.99 ± 0.15     1.71 ± 0.12 0.0006 
TC:HDL-C     3.33 ± 0.18     3.05 ± 0.14 0.0023 
MDA (µmol∙L
-1
)     0.73 ± 0.06     0.71 ± 0.07 0.79 
 





Table 4. Dietary data of 39 men and women before and during the final seven days of a 21-day 
Daniel Fast 
 
Variable Pre During P value 
Kilocalories 1857.6 ± 94.4 1601.7 ± 84.7 <0.01 
Protein (g)   79.4 ± 6.2   53.0 ± 3.4 <0.01 
Protein (%)   16.7 ± 0.7   13.2 ± 0.5 <0.01 
Carbohydrate (g)   229.2 ± 12.5   240.5 ± 14.1 0.35 
Carbohydrate (%)   49.5 ± 1.0   60.7 ± 1.7 <0.01 
Fiber (g)   20.7 ± 1.7   40.0 ± 2.5 <0.01 
Sugar (g)   81.6 ± 5.7   73.2 ± 5.2 0.15 
Fat (g)   66.6 ± 3.8   54.9 ± 4.7 0.02 
Fat (%)   32.2 ± 0.8   30.1 ± 1.7 0.25 
SFA (g)   21.0 ± 1.3     8.4 ± 0.8 <0.01 
Monounsaturated Fat (g)   13.7 ± 1.6   18.3 ± 2.7 0.07 
PUFA (g)     6.7 ± 0.5     9.2 ± 1.0 0.01 
Trans Fat (g)     0.9 ± 0.2     0.2 ± 0.1 <0.01 
Omega 3 (g)     0.5 ± 0.1     0.6 ± 0.1 0.81 
Omega 6 (g)     4.8 ± 0.4     6.0 ± 0.9 0.13 
Cholesterol (mg)   224.4 ± 21.0   12.2 ± 5.1 <0.01 
Vitamin C (mg)   64.5 ± 5.6   140.6 ± 11.1 <0.01 
Vitamin E (mg)     5.7 ± 0.8     7.7 ± 0.8 0.03 
Vitamin A (RE)   362.0 ± 42.4   485.5 ± 52.1 0.02 
Selenium (µg)   46.9 ± 4.9   38.4 ± 9.1 0.35 
 



















Table 5. Pre-intervention blood lipid data in investigations featuring krill oil supplementation 
 
Variable Bunea et al. 
(2004)* 
Skarpańska 
et al. (2010) 






) 247.4 166.3 193.0 173.1 
LDL-C (mg·dL
-1
) 182.9 83.9 119.0 100.6 
Triglycerides (mg·dL
-1
) 160.4 97.0 97.4 82.5 
 
Values are presented as mean (SEM data not available for all studies). 
 








APPENDIX B – EXTENDED LITERATURE REVIEW 
OVERVIEW OF FASTING 
The pioneering work of McCay and colleagues demonstrated that restricting dietary 
intake without inducing malnutrition (i.e., fasting) increases longevity in rats (1).  Since then, 
countless investigations have examined this dietary regimen as a potential treatment for 
extending human life and/or reducing the occurrence of human diseases.  These investigations 
have typically manipulated dietary intake in one of two ways.  The more common form of 
manipulation reduces energy intake without restricting the types of foods that may be consumed.  
Caloric restriction (CR) regimens and alternate-day fasting (ADF) regimens both fit this model.  
The less common form of manipulation restricts the types of foods that may be consumed 
without necessarily affecting total caloric intake.  This form of manipulation is commonly 
referred to as dietary restriction (DR).  These two forms of dietary manipulation can be observed 
in religiously-motivated fasts.  Indeed, Islamic Ramadan can be described as a variant of ADF, 
while the principal fasting periods of Greek Orthodox Christianity (GOC) as well as the Biblical-
based Daniel Fast can each be described as a form of DR.   
Caloric Restriction 
CR is by far the most commonly studied dietary regimen designed to decrease caloric 
consumption.  Under this regimen, daily caloric intake is typically reduced by 20-40% of ad 
libitum consumption (2).  CR investigations have studied species from three Kingdoms 
(Animalia, Fungi, and Protoctista) (3), with rodents being the most commonly studied species.  
Typically, investigations featuring nonhuman species initiate CR as early in life as the subjects 
can tolerate the reduced caloric intake without starving, and this feeding pattern continues until 





The health-promoting effects of CR are profound and wide-ranging.  In fact, CR can 
increase maximum lifespan in species ranging from yeast to nonhuman primates by up to 50% 
(5).  Regarding cardiovascular health, the following changes have been noted following a CR 
regimen: decreases in heart rate (HR) and blood pressure (BP); increases in HR variability; and 
improvements in left ventricular function, post-exercise recovery of both HR and BP, and flow-
mediated vasodilation (6).  Regarding glucoregulatory health, CR has been shown to decrease 
fasting glucose and insulin levels, increase insulin sensitivity, decrease body fat percentage, and 
lower the incidence of diabetes (7, 8). 
CR also elicits favorable changes in blood lipids.  Specifically, CR reduces plasma total 
cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TAG), and the total 
cholesterol:high-density lipoprotein cholesterol (TC:HDL-C) ratio, while having no effect on 
plasma high-density lipoprotein cholesterol (HDL-C) (9) .  Little is currently known about the 
effects of CR on plasma very low-density lipoprotein cholesterol (VLDL-C).   
Markers of oxidative stress have been reported to decrease following a CR regimen, such 
as lipofuscin, malondialdehyde (MDA), superoxide (O2
•-
), and hydrogen peroxide (H2O2) (10).  
In fact, the ability of CR to extend life is theorized by many to be mediated through its ability to 
attenuate oxidative stress (11).  
Despite CR’s favorable and multifarious effects on health, one substantial shortcoming is 
the austerity of this dietary regimen.  Simply put, few humans are willing to reduce their caloric 
consumption by 20-40% for any notable length of time (2).  This shortcoming has given birth to 
alternative dietary regimens, which are designed to replicate the health-promoting effects of CR 







Like CR, ADF regimens reduce caloric intake, but this reduction occurs every other day.  
On “feast days,” subjects may consume food ad libitum; but on “fast days,” food consumption is 
reduced or eliminated altogether.  Two subtypes of ADF exist: “true” ADF regimens completely 
disallow food consumption during fast days, whereas “modified” ADF regimens typically allow 
for the consumption of 15-25% of baseline requirements (12).  Humans and rodents are the two 
most commonly studied species of ADF investigations.  Rodent trials typically initiate ADF 2-3 
months after birth, and this feeding pattern commonly lasts between 8 and 20 weeks (13).  
Human trials have performed ADF for a period ranging from 2-8 weeks (14).  Some 
investigations have reported that rodents on ADF regimens gorge themselves during feast days 
and therefore avoid losing bodyweight (13).  In contrast, humans appear to lose weight when 
undergoing ADF for 3 weeks or longer (13).  Due to the fact that participants are in a calorie-
reduced state for only half of the time under ADF, this dietary regimen may prove to be more 
tolerable for humans than CR (14).  However, no investigation to date has directly compared the 
tolerability of both dietary regimens in humans. 
Initial investigations suggest that the health-related benefits of ADF are very comparable 
to those of CR (15, 16).  ADF regimens increase longevity in some strains of mice, and this 
increase appears to be largely affected by genotype and the time at which ADF was initiated 
(13).  Regarding cardiovascular health, ADF has been shown to decrease HR and BP in rats by a 
similar magnitude to the decrease observed in a 40% CR regimen (16).  Also, ADF regimens 
have been reported to increase HR variability and attenuate the development of post-infarct 
chronic heart failure in rodents (17, 18).  In humans, ADF was reported to lower systolic (but not 





normotensive individuals (19).  Regarding glucoregulatory health, ADF has been shown to 
decrease plasma glucose and insulin in rodents by a similar magnitude to the decrease observed 
in a 40% CR regimen (15).  Human trials have reported that ADF does not affect plasma glucose 
and may or may not decrease plasma insulin (13).  Alternate-day fasting may have gender-
specific effects on glucoregulatory function.  For example, ADF improved insulin sensitivity in 
men but had no effect on this variable in women (13).  Furthermore, glucose tolerance was 
unchanged in men partaking in an ADF regimen, but women partaking in the same regimen 
experienced impaired glucose tolerance (13).        
Like CR, ADF favorably affects blood lipids and appears to attenuate oxidative stress.  
ADF has been reported to decrease TC, LDL-C, and TAG, while increasing HDL-C (20).  
However, no study to date has examined the effects of ADF on VLDL-C, the TC:HDL-C ratio, 
or the LDL-C:HDL-C ratio.  Regarding oxidative stress, levels of the following markers of 
oxidative damage have been observed to decrease on an ADF regimen: protein-bound carbonyls, 
nitrotyrosine, 8-isoprostane, histidine adducts, and lysine 4-hydroxynonenal adducts (21).  
Dietary Restriction 
As mentioned above, DR is a restriction of the types of food (typically macronutrients) 
that may be consumed without necessarily affecting total caloric intake.  Few investigations 
continue to examine carbohydrate restriction or lipid restriction, because research suggests that 
neither form of restriction extends life (22).  On the other hand, protein restriction (PR) has been 
reported in numerous studies to increase longevity (23).  While PR regimens reduce the dietary 
intake of all amino acids, methionine restriction (MR) regimens only reduce the dietary intake of 
the amino acid methionine.  Current investigations are examining whether MR can elicit 





Protein intake has been reduced anywhere from 40-85% in PR investigations, while MR 
investigations often restrict methionine intake by either 40% or 80% (23).  Rodents are the most 
commonly studied species in both PR and MR investigations; both forms of restriction are 
typically initiated during or immediately following the weaning phase and continue until death.  
PR increases lifespan by approximately 20%, suggesting that it accounts for half of the (40%) 
life extension commonly observed in CR regimens (23).  Initial investigations of MR have found 
a similar extension in (22).  Interestingly, one study found that a 40% restriction of all dietary 
amino acids except methionine had no effect on either mitochondrial reactive oxygen species 
generation or oxidative damage in mitochondrial deoxyribonucleic acid (DNA) (24).  The 
authors of this investigation concluded that the reduction of methionine intake may account for 
all of the life extension observed in PR regimens (24). 
Few (if any) investigations have examined the effects of PR or MR on blood lipids.  
However, both PR and MR have been shown to lower markers of oxidative stress.  Specifically, 
PR for seven weeks has been reported to lower liver mitochondrial H2O2 production, free radical 
leak, and 8-oxo-7,8-dihydro-2’-deoxyguanosine in both nuclear and mitochondrial DNA (25).  
Also, 6-7 weeks of MR has been reported to lower heart and liver mitochondrial H2O2 
production, free radical leak, 8-oxo-7,8-dihydro-2’-deoxyguanosine in mitochondrial DNA, 









Religious fasts are partaken chiefly for spiritual betterment, but they can also 
substantially impact physical health (27).  During the past 20 years, investigations have 





three principal fasting periods of GOC, and 3) the Biblical-based Daniel Fast.  Ramadan and the 
fasting periods of GOC will both be discussed in this section.  However, because the Daniel Fast 
is the main focal point of this text, this specific form of fasting will be discussed at the 
conclusion of this literature review. 
Ramadan 
Muslims abstain from consuming food or drink from sunrise (Sahur) to sunset (Iftar) 
during the holy month of Ramadan, which lasts between 28 and 30 days.  The first day of 
Ramadan advances 11 days each year due to the fact that the Islamic lunar calendar (Hijra) is not 
synchronized with the Gregorian calendar.  As a consequence, Ramadan falls on different parts 
of the year over a 33-year cycle.  Ramadan can be considered to be a variant of ADF, because it 
alternates periods in which food consumption is allowed ad libitum with periods in which food 
consumption is completely disallowed.  The feast and fast periods of Ramadan are each 12 hours 
in length on average (28), equating to half of the length of the 24-hour periods featured in ADF 
regimens.  However, daily fasting time can vary considerably from investigation to investigation, 
as it is highly dependent upon a location’s latitudinal distance from the equator as well as the 
part of the seasonal year that Ramadan occurs. 
A common dietary practice during Ramadan is to consume a large meal at dusk and a 
smaller meal before dawn (29), although some Muslims consume an additional meal before 
sleeping (30).  These meals can be described as celebratory feasts that are often partaken in the 
company of family and close friends (31).  A greater variety of foods is consumed during these 
meals (32), and sugary foods are consumed more frequently (33). 
All healthy, adult Muslims are required to fast during Ramadan.  Individuals who are 





(34).  These individuals perform a compensational fast if and when they are able to do so.  
However, many Muslims who are eligible for exemption decide nonetheless to fast during 
Ramadan due to social pressure and the desired camaraderie of fasting with family and friends 
(34). 
The collective body of research on Ramadan fasting has noted mostly heterogeneous 
findings regarding dietary intake and health-related outcomes, making it difficult to draw 
definitive conclusions about the health-related effects of this fast (27).  Much of the 
heterogeneity of findings can likely be attributed to differences between investigations in daily 
fasting time as well as differences in the following subject characteristics: food choices, smoking 
status, and oral medication consumption (27). 
Only one investigation to date has examined the effects of Ramadan fasting on markers 
of oxidative stress.  The authors of this investigation reported reduced levels of MDA in 
erythrocytes, although no changes were noted regarding serum MDA or plasma protein-bound 
carbonyls (29).   
Greek Orthodox Christianity 
 The three principal fasting periods of GOC have similar food proscriptions to one 
another.  During the Nativity fast (40 days), dairy products, eggs, and meat are proscribed every 
day, while fish and olive oil are also forbidden on Wednesdays and Fridays.  During Lent (48 
days), dairy products, eggs, and meat are proscribed.  Olive oil may be consumed only on 
weekends during this period, and fish may be consumed only on March 25
th
 and Palm Sunday.  
During the Assumption (15 days), dairy products, eggs, and meat are proscribed.  Olive oil may 
be consumed only on weekends during this period, and fish may be consumed only on August 
6
th





vegetables during these periods (35).  Thus, each principal fasting period can be described as a 
variant of vegetarianism and a form of DR. 
 Only six investigations to date have directly examined the health-related effects of the 
GOC fasts.  Three studies examined the effects of all three principal fasting periods (35-37), two 
studies examined the Nativity fast only (38, 39), and one study compared a fasting week during 
Lent with a non-fasting week (40).  Clearly, more research remains to be performed, but the 
results thus far have been promising.    
 Little is known about the effects of GOC fasting on either cardiovascular or 
glucoregulatory health.  GOC fasting may or may not increase systolic BP and may or may not 
decrease diastolic BP (37, 40).  In addition, heterogeneous findings have been reported regarding 
plasma glucose levels (35, 39, 40).  Regarding blood lipids, it appears that TC and LDL-C 
decrease during the fasting periods, but the LDL-C:HDL-C ratio does not appear to change (35, 
39, 40).  Also, conflicting findings have been reported regarding both HDL-C and the TC:HDL-
C ratio as well as TAG (35, 39, 40).  Although no study to date has examined oxidative stress in 
response to GOC fasting, a recent study measured serum antioxidant levels before and after the 
Nativity fast (39).  This investigation found that serum retinol, the retinol:TC ratio, serum α-
tocopherol, and the α-tocopherol:TC ratio each decreased following this fast.  
 
OVERVIEW OF BLOOD LIPIDS 
 A lipid panel is one blood test that is used to partially assess an individual’s likelihood of 
developing cardiovascular disease (CVD).  In particular, lipid panels commonly measure serum 
levels of LDL-C, HDL-C, VLDL-C, TC, and TAG.  Each of these variables contributes either 





promotion of cardiovascular health.  This section of the review will discuss each aforementioned 
lipid panel component, as well as non-HDL cholesterol (non-HDL-C), the TC:HDL-C ratio, and 
the LDL-C:HDL-C ratio. 
Low-Density Lipoproteins 
 The main function of LDL-C is to transport cholesterol from the liver and intestines to 
areas of need (41).  However, LDL-C does not always reach its intended target and instead 
becomes trapped in the arterial intima, an early step in the development of atherosclerosis (42).  
Atherosclerosis eventually leads to the formation of a thrombus, which can result in the 
development of several cardiovascular events, including myocardial infarction and stroke (43).   
It is of no surprise then that elevated LDL-C levels are associated with an increased risk 
of atherosclerotic heart disease and an increased occurrence of cardiovascular events (44, 45).  
Accordingly, the Adult Treatment Panel III of the National Cholesterol Education Program 
(NCEP) recommends that serum LDL-C be less than 100 mg·dL
-1
 for optimal cardiovascular 
health (46).  However, the mean level of serum LDL-C among U.S. adults is 120.8 mg·dL
-1
, and 
70.9% of this population has serum LDL-C levels above the recommended 100 mg·dL
-1
 (47).  
Lowering LDL-C in individuals with elevated values could substantially reduce the risk of 
developing a cardiovascular-related disorder.  In fact, a 38.67 mg·dL
-1
 decrease in LDL-C was 
demonstrated to reduce the risk of coronary heart disease (CHD) death by 19% and all-cause 
mortality by 12% (45).        
Several pharmaceutical options for lowering LDL-C are currently available.  HMG-CoA 
reductase inhibitors (18-55% reduction), better known as “statins,” lower the body’s endogenous 
production of cholesterol (48).  Bile acid sequestriants (15-30% reduction) prevent intestinal 





acids (48).  Cholesterol absorption inhibitors (18% reduction) block the intestinal absorption of 
dietary and biliary cholesterol (49).  Although its mechanism of action is currently unclear, 
niacin has been shown to lower LDL-C between 5 and 25% (48).  The mechanism of action for 
fibric acid derivatives is also currently unknown, but these pharmaceuticals have been reported 
to reduce LDL-C between 5 and 20% (48).   
Multiple non-pharmacological interventions have been shown to moderately decrease 
LDL-C.  Intake of the following foods has been associated with a decline in LDL-C: 
polyunsaturated fats, omega 3 fatty acids, low-glycemic fruits and vegetables, soluble-fiber (5-
10% reduction), phytosterols (up to 13%), nuts (2-19%), and soy protein (6%) (50, 51).  In 
addition, supplementation of the following nutraceuticals has been demonstrated to lower LDL-
C: tocotrienol (8-27% reduction), pantethine (20-27%), red-yeast rice (22-32%), ginseng (10%), 
probiotics (5-8%) and sesame oil (10%) (50).  Resistance exercise appears to have a minimal 
effect on LDL-C, while aerobic exercise can reduce this cholesterol by approximately 5% (52).     
High-Density Lipoproteins 
 The ability of HDL-C to protect against atherosclerosis is mainly mediated through its 
role in reverse cholesterol transport.  Through this process, HDL-C travels throughout the 
bloodstream and gathers cholesterol from areas of overabundance, including atherogenic foam 
cells (53).  HDL-C then transports this cholesterol to the liver, where it is converted into bile and 
excreted (54).  In addition to its role in reverse cholesterol transport, HDL-C helps protect 
against inflammation, LDL oxidation, and thrombosis (54).  Also, HDL-C increases nitric oxide 
production and inhibits the expression and migration of atherosclerotic adhesion molecules (53).     
 As would be expected, HDL-C levels are inversely correlated with the risk of CHD (46).  
In fact, a 1 mg·dL
-1





and women, respectively (55).  For optimal cardiovascular health, HDL-C should be ≥40 mg∙dL
-
1
, but approximately one-third of men and one-fifth of women have HDL-C levels below this 
threshold (46).        
 The pharmacological increase in HDL-C has been the subject of numerous investigations 
over the past decade.  Statins raise HDL-C by 5-15%, while niacin increases this cholesterol by 
15-35% (53).  Fibrates (10-15% increase) activate peroxisome proliferator-activated receptor 
(PPAR)- , which in turn up-regulates hepatic HDL synthesis (53).  Thiazolidnediones increase 
HDL-C in insulin-resistant individuals by activating PPAR-λ (53).  The two forms of 
thiazolidnediones currently in use are pioglitazone and rosiglitazone.  Pioglitazone has been 
reported to increase HDL-C by 4.6 mg·dL
-1
, while rosiglitazone has been shown to increase 
HDL-C by 2.7 mg·dL
-1
. However, rosiglitazone may or may not significantly increase the risk of 
myocardial infarction (53).  Glitazars combine the effects of fibrates and thiazolidnediones by 
activating both PPAR-α and PPAR-λ.  These drugs have been demonstrated to increase HDL-C 
by 13-31%, but the following side effects have been noted: edema, anemia, leucopenia, and 
weight gain (53).  Also, increased occurrences of death, cardiovascular events, and congestive 
heart failure have been noted with these drugs (53).  Cholesteryl ester transfer protein (CETP) 
inhibitors increase HDL-C by suppressing the transfer of cholesteryl esters from HDL to 
intermediate low-density lipoprotein, LDL, and VLDL (56).  Torcetrapib, dalcetrapib, and 
anacetrapib are the three forms of CETP inhibitors that have been investigated to date.  Despite 
raising HDL-C by 72.1%, torcetrapib has been shown to increase all-cause mortality and the 
occurrence of cardiovascular events (53).  In two separate trials, dalcetrapib has been reported to 
increase HDL-C by 28% and 34% (53).  Anacetrapib has been shown to elevate HDL-C by 





HDL infusion is one of the more promising treatments aimed at increasing HDL-C.  This 
treatment has been demonstrated to increase nitric oxide bioavailability, stimulate reverse 
cholesterol transport, reduce inflammation, and improve glycemic control (53).  Also, 
recombinant apolipoprotein A-I Milano infusion has been found to reduce coronary atheroma 
burden (53).   
Some non-pharmacological interventions have had moderate success at elevating HDL-C.  
Diets featuring plentiful amounts of unsaturated fats (particularly omega 3 fatty acids) and low 
glycemic index carbohydrates may increase HDL-C levels (53).  In fact, a recent investigation 
reported that substituting 13% of total energy intake as carbohydrate with monounsaturated fat 
(predominantly in the form of sunflower oil) in a “portfolio” diet for four weeks increased HDL-
C by 12.5% (57).  Aerobic exercise without weight loss may or may not minimally increase 
HDL-C; however, weight loss induced by both aerobic exercise (4.6 ± 1.2 mg·dL
-1
) and diet (5.0 
± 1.2 mg·dL
-1
) have been shown to raise this cholesterol (58, 59).  Cigarette smoking cessation 
appears to raise HDL-C by 4 mg·dL
-1
 (53).  Increases in HDL-C have been noted following the 
supplementation of the following nutraceuticals: phosphatidylinositol (up to 17.8%) (60); soy 
lecithin (4.4-14%) (61, 62); a calcium and vitamin D combination (~5%) (63); red-yeast rice (5.8 
mg·dL
-1
) (64); a combination of vitamin C, vitamin E, coenzyme Q10, and selenium (65); 
policosanol (8-29%) (66); and krill oil (67).  Regarding policosanol, numerous investigations 
conducted by one research group have reported HDL-C raising benefits, but the majority of 
external research groups have been unable to replicate these findings (68).      
Krill oil deserves special mention as a potential HDL-C-raising supplement.  This 
nutrient, which is extracted from Antarctic krill, contains a plentiful amount of omega 3 fatty 





allows them to be better-absorbed by the intestine and more readily incorporated into cell 
membranes (69).  Krill oil supplementation at a dosage of 1-3 g·d
-1
 for 90 days was reported to 
increase HDL-C between 43-60% (67).  However, two recent studies (70, 71) found that krill oil 
supplementation (1 g·d
-1
 for 42 days and 3 g·d
-1
 for 49 days, respectively) had no effect on HDL-
C.      
Triglycerides, Very Low-Density Lipoproteins, and Non-High-Density Lipoproteins    
 Elevated TAG increases the risk of CVD via direct and indirect means.  Directly, TAG 
partners with VLDL-C and CETP to make LDL-C more atherogenic and HDL-C less anti-
atherogenic (72).  Specifically, VLDL (with the aid of CETP) exchanges its TAG-rich 
lipoprotein particles for cholesterol esters from LDL-C and HDL-C.  Once these lipoproteins 
encounter hepatic lipase, they are stripped of their TAG particles, rendering them much smaller 
than normal.  This removal of TAG makes it easier for LDL-C to enter the arterial wall and 
lowers the amount of cholesterol that HDL-C can transport back to the liver.  Also, postprandial 
hypertriglyceridemia promotes CVD (as well as type 2 diabetes mellitus [T2DM]) by elevating 
postprandial oxidative stress (73), a phenomenon that will be discussed later in this review.  
Indirectly, hypertriglyceridemia has high correlations with several risk factors of CVD, including 
obesity, metabolic syndrome, biomarkers of inflammation and thrombosis, and T2DM (74).   
 The Adult Treatment Panel III of the NCEP recommends that serum TAG equal 150 
mg·dL
-1
 or less (46).  Unfortunately, 30.0% of Americans aged 20 or older are estimated to have 
serum TAG > 150 mg·dL
-1
 (75).  This prevalence increases to 42.8% in Americans aged 50 or 
older (76).  A meta-analysis of 21 investigations found that an 89 mg·dL
-1
 increase in serum 
TAG was associated with a 32% and 76% increased risk of CHD in men and women, 





increased risk in men and women, respectively) even after controlling for TC, LDL-C, HDL-C, 
body mass index, and diabetes (78). 
 Many of the pharmacological options for lowering LDL-C have also been demonstrated 
to lower TAG.  Indeed, statins (7-30% reduction), fibrates (20-50%), niacin (20-50%), and 
cholesterol absorption inhibitors are effective TAG-lowering options (79).  In addition, several 
non-pharmacological interventions have TAG-reducing effects.  Many dietary regimens with 
varying macronutrient compositions have been proposed to reduce TAG (reviewed in [79]).  
Dietary regimens rich in omega 3 fatty acids as well as monounsaturated and polyunsaturated 
fats appear to be particularly effective in this regard.  Decreases in TAG have been reported 
following supplementation of the following: fish oil (up to 50% reduction), soy protein (10.5%), 
dietary fiber, and red yeast rice (up to 34.1%) (79).  In addition, garlic supplementation may or 
may not lower TAG (79).  Weight loss and regular exercise of moderate intensity (4-7 kcal·min
-
1
) are also recommended as TAG-reducing interventions (46).      
 As mentioned above, VLDL-C teams with TAG and CETP to promote CVD.  For 
individuals with serum TAG < 400 mg·dL
-1
, VLDL-C is often estimated by dividing TAG levels 
by 5 (46).  This method becomes inaccurate once serum TAG levels exceed 400 mg·dL
-1
, 
necessitating that VLDL-C be measured directly (46).  VLDL-C should be ≤ 30 mg·dL
-1
 for 
optimal cardiovascular health (46).  However, VLDL-C is not frequently considered by 
clinicians as an independent risk factor for developing CVD; instead, non-HDL-C, which is the 
sum of VLDL-C, LDL-C and all other apolipoprotein B-containing proteins, is more commonly 
used to predict CVD risk.  Indeed, non-HDL-C has been shown to be a better predictor of 
coronary mortality than LDL-C (46).  For optimal cardiovascular health, non-HDL-C, which is 
calculated as TC minus HDL-C, should be < 130 mg·dL
-1







in non-HDL-C is associated with a 19% and 15% increased risk in cardiovascular mortality in 
men and women, respectively (80).  Interventions that have been demonstrated to lower LDL-C 
and/or TAG are excellent options for lowering non-HDL-C.  In particular, statins, which have 
been demonstrated to substantially lower LDL-C and VLDL, are an outstanding first line of 
defense (80).       
Total Cholesterol and Cholesterol Ratios 
Recommendations state that TC, the sum of all lipoproteins, should be < 200 mg·dL
-1
 for 
optimal cardiovascular health (46).  Moreover, epidemiological studies have found that a 1% 
reduction in TC is associated with a 2% reduction in CHD risk (46).  However, TC is a flawed 
predictor of an individual’s risk of CVD, because it does not differentiate between atherogenic 
lipoproteins (non-HDL-C) and anti-atherogenic lipoproteins (HDL-C).  In fact, 35% of CHD 
patients have a TC below 200 mg·dL
-1
 (81). 
By contrast, cholesterol ratios such as the TC:HDL-C ratio and LDL-C:HDL-C ratio take 
atherogenic and anti-atherogenic components into account.  Consequently, these ratios serve as 
better predictors of CVD than TC, LDL-C, and HDL-C alone (82).  When compared to each 
other, the TC:HDL-C ratio and LDL-C:HDL-C ratio are equally effective at predicting CVD 
(82).  This should come to no surprise, as LDL-C is highly correlated with TC (46).  However, in 
individuals with serum TAG > 300 mg·dL
-1
, the TC:HDL-C ratio is a better predictor of 
cardiovascular events than the LDL-C:HDL-C ratio, because LDL-C cannot be calculated 
reliably (82).  For men and women, desirable values for the TC:HDL-C ratio are < 4.5 and < 4.0, 
respectively.  Regarding the LDL-C:HDL-C ratio, desirable values for men and women are < 3.0 





In sum, HDL-C promotes cardiovascular health, while LDL-C, HDL-C, VLDL-C, TC, 
and TAG promote CVD.  Non-HDL-C, the TC:HDL-C ratio, and LDL-C:HDL-C ratio are 
superior predictors of a cardiovascular event to many of the individual lipoproteins that comprise 
a lipid panel.  While blood lipids are clearly well-defined clinical measures of CVD risk, one 
emerging risk factor of this disease is oxidative stress.  
 
OVERVIEW OF OXIDATIVE STRESS 
“Reactive oxygen and nitrogen species” (RONS) is an umbrella term that encompasses 
oxygen radicals, nitrogen radicals, and their nonradical derivatives (83).  Although RONS can 
perform useful functions such as initiating cellular signaling and defending against harmful 
agents, an overexpression of this species can cause damage to lipids, protein, DNA, and other 
molecules (84).  To prevent this, organisms are equipped with antioxidant defense systems that 
scavenge RONS.  However, the balance between RONS expression and antioxidant scavenging 
can become disturbed if RONS production is increased and/or the antioxidant defense system is 
weakened (85).  This undesirable phenomenon, which is referred to as “oxidative stress,” has 
been linked to over one-hundred diseases as well as the aging process (84, 86).  This section of 
the review will summarize the current knowledge pertaining to the relationship between 
oxidative stress and human health.  In particular, the following will be discussed: 1) RONS 
production, 2) postprandial oxidative stress, 3) implications for health and disease, 4) measuring 










 Within an atom, electrons spin around the nucleus in defined regions known as orbitals.  
For most atoms and molecules, each orbital contains a pair of electrons that spin in opposite 
directions, which cancels each electron’s magnetic field and maintains stability within the atom 
or molecule; such species are said to be nonradicals (87).  A free radical (hereafter referred to as 
a radical), then, is any species capable of free existence that contains one or more electrons that 
spin alone and unopposed in an orbital.  Radicals are denoted with a superscript dot (
•





 The presence of one or more unpaired electrons creates instability within a radical.  In an 
effort to regain stability, the radical typically reacts with another molecule (often a nonradical) in 
one of two ways: 1) by donating its lone electron(s) to the other molecule or 2) by extracting one 
or more electrons from the other molecule to pair with its lone electron(s).  Thus, when radicals 
react with nonradicals, the nonradical either gains or loses an electron and converts to a radical.  
This cycle continues indefinitely until a termination reaction occurs, which can happen in one of 
two ways: 1) two radicals react with each other or 2) a radical reacts with an antioxidant. 
Superoxide, Hydrogen Peroxide, and the Hydroxyl Radical 
 If radicals can generate new radicals, then how is the first radical produced?  The answer 
to this question can be found in the mitochondrion (reviewed in [88]).  During cellular 
respiration, electrons move throughout the transport chain and provide energy to pump protons 
from the mitochondrial matrix to the intermembrane space.  At certain sites within the transport 
chain, carriers are only able to transport one electron at a time.  An estimated 1-3% of these 
single electrons “leak” to oxygen and form O2
•-





 Considered to be the “primary” RONS, O2
•-
 generates “secondary” RONS through its 
interaction with other molecules (84).  For example, O2
•-
 undergoes dismutation via superoxide 
dismutase to form H2O2.  By themselves, O2
•-
 and H2O2 are not particularly toxic.  In fact, neither 
species is able to damage DNA or lipids (83).  Nonetheless, O2
•-
 and H2O2 pose danger due to 
their respective abilities to form more toxic RONS.  While a complete listing of all of the RONS 
that are generated from these two species is beyond the scope of this review, the highly reactive 
hydroxyl radical (OH
•
) is worthy of mention.     
 O2
•-
 and H2O2 produce OH
•
 in vivo mainly via the Haber-Weiss reaction.  First, O2
•-
 







 + O2   [1] 











  [2] 
Thus, the net reaction is:  
  O2
•-




 + O2  [3] 
OH
•
 is the most reactive oxygen species in existence.  In fact, OH
•
 reacts with the first 
thing it comes into contact with immediately after it is formed (89).  Consequently, whether OH
•
 
attacks DNA, lipids, protein, or something else depends entirely on what is immediately 
proximal to this radical upon its formation.  Few (if any) antioxidants can prevent OH
•
 from 
reacting with another molecule, which means that damage is virtually unavoidable once this 
radical has been formed (83).   
Postprandial Oxidative Stress 
 RONS formation can be acutely increased in response to several stressors, including 





cigarette smoke, radiation, and ozone (83).  Another stressor known to increase RONS 
production that has recently received considerable interest from the scientific community is the 
metabolism of a consumed meal.  Indeed, RONS production has been demonstrated to increase 
following the postprandial metabolism of carbohydrate, lipid and protein ingested either alone or 
combined with other macronutrients (73).   The excessive RONS formation and subsequent 
oxidative damage caused by this postprandial metabolism is termed postprandial oxidative stress.  
 Postprandial oxidative stress is a cyclical phenomenon (reviewed in [73]).  That is, the 
postprandial elevation of RONS activates certain pathways – such as cellular adhesion, gene 
transcription, and inflammation – that in turn lead to additional RONS generation.   This cycle is 
believed to initiate in response to the gathering of substrates (i.e., glucose and/or free fatty acids 
[FFA]) within the peripheral tissues and/or vasculature.  For both sites of RONS production, the 
metabolism of a high-calorie meal rich in carbohydrate and/or lipid hastens the processing of 
these substrates through the electron transport chain.  Given that electron leakage and subsequent 
O2
•-
 production occur even during basal metabolism, the accelerated postprandial metabolism is 
thought to lead to even greater levels of O2
•-
 production (73).  This accelerated production of O2
•-
 
is exacerbated in the vasculature, because the endothelium lacks the ability to restrict the entry of 
substrate, particularly glucose (73).  It follows that excessive intake of high-energy foods rich in 
dietary fat and carbohydrate may exacerbate the production of RONS and lead to increased 
oxidative stress over time.  To the contrary, restriction of dietary energy and/or certain 
macronutrients (e.g., fat) may be associated with a decrease in RONS production and subsequent 







Implications for Health and Disease 
 As mentioned above, oxidative stress can inhibit the regular function of lipids, protein, 
and DNA (84).  Such inhibition can lead to deleterious effects, including the pathogenesis of 
various diseases.  The roles of oxidative stress in the pathogenesis of diabetes, CVD, and the 
aging process merit further discussion. 
Diabetes and Cardiovascular Disease 
 The “common soil” hypothesis postulates that T2DM and CVD share common 
antecedents, particularly postprandial oxidative stress (reviewed in [90]).  When an excessive 
amount of O2
•-
 is produced in response to the metabolism of a high fat and/or high carbohydrate 
meal, the body inhibits beta-oxidation in order to curb additional O2
•-
 production.  Such an 
inhibition increases intracellular FFA, which in turn reduces glucose transporter type 4 
translocation.  The reduction in this translocation may lead to impaired glucose uptake into tissue 
and may possibly lead to insulin resistance, which can be viewed as a defense mechanism against 
additional oxidative stress.      
 As a response to insulin resistance, the pancreas releases greater levels of insulin in an 
effort to maintain normal glucose tolerance.  However, impaired glucose tolerance eventually 
occurs once insulin resistance increases to a level that can no longer be compensated for by 
additional insulin secretion (90).  This pre-diabetic condition is characterized by postprandial 
hyperglycemia: fasting serum glucose is normal, but postprandial serum glucose is elevated.   
 Postprandial hyperglycemia combined with increased levels of FFA can result in 
increased RONS production.  This poses a particular threat to β cells, which have low levels of 
antioxidant enzymes to scavenge these RONS (90).  Consequently, the oxidative stress caused by 





production, content, and secretion (90).  Impaired insulin secretion, coupled with insulin 
resistance, eventually leads to the development of overt T2DM. 
 Type 2 diabetes mellitus, which is characterized by fasting and postprandial 
hyperglycemia, elevates RONS production through two mechanisms: 1) via the exposure of 
endothelial cells to glucose and FFAs, and 2) via the production of advanced glycation end 
products (AGE) (reviewed in (91).  The additional RONS promote endothelial dysfunction by 
inactivating endothelial nitric oxide and inhibiting nitric oxide formation, endothelial nitric oxide 
synthase, and prostacyclin synthetase.  Such dysfunction eventually causes atherosclerosis and 
CVD via the following: impaired endothelium-dependent vasodilation, increased adhesion 
molecule expression, increased adhesion of monocytes and platelets, and increased LDL 
oxidation.    
To summarize, the consumption of a high fat and/or high carbohydrate meal elevates 
RONS production, which in turn damages endothelial cells and β cells.  Damage to β cells leads 
to overt T2DM, which in turn may cause further elevations in RONS production and greater 
damage to endothelial cells.  Damage to the endothelium may eventually cause atherosclerosis 
and CVD.  Therefore, oxidative stress (postprandial in particular) may be viewed as the common 
soil of T2DM and CVD. 
Aging 
 The Oxidative Stress Theory of Aging (OSTA) postulates that organisms age due to the 
accumulation of oxidative damage over time.  Three main predictions are associated with this 
theory (reviewed in [92]):  
I. Oxidative damage will increase with age.  This increase could result from elevated RONS 







II. Interventions that increase lifespan will reduce oxidative damage.  This reduction could 
result from decreased RONS production, increased antioxidant activity, and/or increased 
repair/turnover of oxidative-damaged molecules 
 
III. Attenuating oxidative stress will increase lifespan.  Conversely, increasing oxidative 
stress will decrease lifespan.  Alterations in oxidative stress can be achieved by 
manipulating RONS production, antioxidant levels, and or the repair/turnover of 
oxidative-damaged molecules. 
 
Thus, the validity of this theory rests on the evidence in support of these three predictions.  
The majority of evidence supports the first prediction of the OSTA.  Indeed, lipid 
peroxidation, protein oxidation, and DNA oxidation have been observed to increase with age in 
rats, mice, flies, monkeys, and human tissue (92).  In contrast, some investigations have reported 
no age-related change in DNA oxidation in rodent tissues (93).  However, it is currently believed 
that artifactual DNA oxidation arising during the isolation and analysis of DNA samples is the 
reason why no age-related change was observed in some studies (92).  It should be noted that 
even though the evidence currently supports the first prediction, this does not necessarily prove 
the validity of the OSTA. 
Regarding the second prediction, CR and certain genetic manipulations, both of which 
have been shown to reduce oxidative stress, increase lifespan.  The scientific literature suggests 
that CR reduces lipid peroxidation, protein oxidation, and DNA oxidation in rodents.  
Specifically, this reduction in oxidative damage appears to be due to decreased RONS 
production and/or increased repair/turnover of oxidative-damaged molecules, because CR 
appears to have little to no effect on antioxidant activity (92).  Even though the collective body 
of CR literature supports the second prediction, it is currently unknown whether the life 
extension caused by CR is mediated through attenuated oxidative damage; indeed, other 
biological pathways that are affected by CR could conceivably be responsible for some or all of 





Drosophila, and mice have been reported to live longer and experience attenuations in oxidative 
stress.  However, studies with C. Elegans and Drosophila have yet to definitively demonstrate 
the existence of a physiological mechanism that links attenuated oxidative stress with increased 
lifespan (92).  
While the first two predictions of the OSTA attempted to demonstrate correlation 
between oxidative stress and aging, the third prediction attempted to demonstrate causation.  
Early investigations tried to prove the third prediction by administering antioxidants to animals.  
In theory, consuming exogenous antioxidants would increase tissue levels of these molecules, 
which in turn would decrease the age-related accumulation of oxidative damage and therefore 
increase lifespan (92).  The majority of studies noted no change in lifespan following the 
consumption of exogenous antioxidants, which seemed to disprove the OSTA.  However, these 
studies failed to prove that the exogenous antioxidants did indeed attenuate oxidative damage in 
tissues.  Without this proof, it could not be claimed that the attenuation of oxidative stress fails to 
extend life.  Recent work has utilized recombinant gene technology to alter the expression of 
either antioxidant enzymes or enzymes involved in the repair/turnover of oxidative-damaged 
molecules.  Many of these studies reported that overexpression of antioxidant enzymes increases 
lifespan and that reduced expression of repair enzymes lower lifespan, thus supporting the third 
prediction (92).  However, other studies noted that altering the expression of either type of 
enzyme has no effect on longevity (92).  Unfortunately, few of these investigations examined 
whether altering the expression of these enzymes had any effect on the accumulation of oxidative 
damage.  Again, knowledge of an intervention’s effects on oxidative damage is absolutely 





suggests that organisms age due to the accumulation of oxidative damage over time, more work 
remains to be performed before this belief is accepted as fact. 
Measuring Oxidative Stress 
 The analysis of certain biomarkers can provide insight regarding the localization and 
effects of oxidative damage (86).  These biomarkers can be assayed from a variety of human 
tissues or biological fluids (most commonly blood and urine).  Biomarkers of oxidative stress 
can be categorized into three groups: 1) direct indicators of RONS activity; 2) indirect indicators 
of RONS activity; and 3) the total antioxidant capacity (TAC) (94). 
Direct Indicators of RONS Activity 
Electron spin resonance (ESR) spectroscopy is currently the only available direct method 
for detecting RONS.  This technique determines the presence of unpaired electrons by measuring 
the magnetic properties of a tissue sample.  However, even during conditions of oxidative stress, 
these electrons are often too low in concentration and too unstable to normally be detected by 
ESR spectroscopy in vivo (95).  Fortunately, more stable and more easily detectable radical 
adducts can be formed by adding exogenous “spin traps” to the sample.  Nevertheless, ESR 
spectroscopy is labor intensive and requires expensive equipment; as a consequence, it is not 
commonly used in research settings.    
Indirect Indicators of RONS Activity 
 RONS are typically too unstable and short-lived to be measured directly without utilizing 
techniques such as ESR spectroscopy.  Instead, the more stable molecular end products of 
oxidative damage more commonly serve as biomarkers of oxidative stress (86).  End products of 
lipid peroxidation, protein oxidation, and DNA oxidation are the most frequently assayed 





 Lipid peroxidation involves the abstraction of a hydrogen atom from a fatty acid or a 
fatty acyl side chain (reviewed in [96]).  Most of the time, a newly formed lipid radical will react 
with O2 to form a peroxyl radical.  Peroxyl radicals can react with one another, oxidize 
membrane proteins, or abstract hydrogen from adjacent fatty acid side chains, thus persisting 
lipid peroxidation (96).  The two most commonly measured biomarkers of lipid peroxidation are 
MDA and F2-Isoprostanes (F2-IsoPs).  Malondialdehyde is a byproduct of the peroxidation of 
arachidonic acid, eicosapentaenoic acid, and docosahexanoic acid.  This biomarker is typically 
measured via the thiobarbituric acid reactive substances (TBARS) assay, which has the 
advantages of being relatively inexpensive and easy to perform.  To perform a TBARS assay, the 
sample is heated with thiobarbituric acid under acidic conditions, and a fluorescent red derivative 
(which allegedly represents a [TBA]2-MDA adduct) is spectophotometrically measured by its 
absorbance at 532 nm (96).  However, the TBARS assay has been widely criticized due to the 
fact that several biological molecules – such as amino acids, bile acids, carbohydrates, nucleic 
acids, and certain antibiotics – can react with thiobarbituric acid and produce false-positive 
readings (95).  In an attempt to improve the measurement of MDA (or TBARS), alternative 
procedures have been developed which require a dual wavelength read (97).  F2-IsoPs are 
prostaglandin-like compounds generated in vivo via nonenzymatic peroxidation of arachidonic 
acid (86).  Several methodologies of measuring F2-IsoPs currently exist, including gas 
chromatography-mass spectrometry (MS), liquid chromatography (LC)-MS, enzyme 
immunoassays, and radioimmunoassays.  F2-IsoPs are considered some of the most reliable 
biomarkers of oxidative stress for the following reasons: 1) they can be measured accurately 
down to picomolar concentrations; 2) they are stable in both urine and exhaled breath 





they do not exhibit diurnal variations, nor are they affected by lipid dietary intake; and 4) they 
are present and detectable in all human tissues and biological fluids, thus providing a reference 
of comparison between oxidatively damaged and non-oxidatively damaged samples (86).       
 Proteins are some of the main targets of oxidative modification in vivo, because they are 
abundant in living organisms, and because they have a primary role in most cellular processes 
(86).  RONS can attack protein directly, or they can react with molecules such as lipids and 
sugars to form new products that attack protein (98).  Some oxidative modifications of protein 
cleave the peptide bond, while others modify sidechains.  Oxidative damage to protein is 
typically irreparable and can lead to downstream impairments of a variety of cellular functions 
(86).  The two most commonly measured biomarkers of protein oxidation are protein-bound 
carbonyls and nitrotyrosine.  Several physiological phenomena can result in protein-bound 
carbonyl formation, including oxidation of several amino sidechains, formation of Michael 
adducts, and glycation/glycoxidation of lysine (86).  Protein-bound carbonyls are an attractive 
choice for laboratory measurement, because they remain stable for up to ten years when stored at 
-80°C (86).  These biomarkers are commonly measured via spectrophotometric 2,4-
dinitrophenylhydrazine assay, spectrophotometric 2,4-dinitrophenylhydrazine assay coupled to 
protein fractionation by high-performance liquid chromatography, and one- or two-dimensional 
electrophoresis and Western blot immunoassay (99).  Unfortunately, these methods lack the 
specificity to identify which amino acids were oxidatively attacked as well as which proteins 
were oxidative modified (99).  Regarding nitrotyrosine, its presence was initially thought to be 
ironclad evidence of peroxynitrite formation in vivo.  However, recent work has demonstrated 
that nitrotyrosine can be generated via multiple pathways, some of which do not involve 





linked immunosorbent assay, high-performance liquid chromatography with electrochemical 
detection, MS-based assays, LC-MS, and liquid chromatograph-tandem MS (99).    
 RONS can damage DNA through various mechanisms, including modification of all 
bases, production of base-free sites, deletions, frame shifts, strand breaks, DNA-protein cross-
links, and chromosomal rearrangements (100).  OH
•
 is the main RONS associated with oxidative 
damage.  This radical species has been shown to react with every component of DNA (the purine 
and pyrimidine bases as well as the deoxyribose backbone) (100) and produce a variety of base 
and sugar modification products (101).  Such modification products transform into stable end 
products, which can serve as biomarkers of DNA oxidation.  Unfortunately, the relative amounts 
of these end products depend not simply on the magnitude of DNA damage, but also on reaction 
conditions (101).  As a consequence, no single end product should be considered the sole piece 
of evidence pertaining to the magnitude of DNA oxidation that occurred.  Nonetheless, many 
investigations have only measured 8-hydroxy-2’-deoxyguanosine (8OHdG) to indicate oxidative 
damage to DNA (101).  This biomarker is most commonly collected via urine sampling.  One 
advantage of this form of sampling is that urinary 8OHdG does not appear to be affected by 
acute changes in diet (101).  However, urinary 8OHdG may not accurately reflect levels of DNA 
oxidation, because this biomarker can also arise from the degradation of oxidized 
deoxyguanosine triphosphate in the DNA precursor pool (101).  Common methods for assaying 
urinary 8OHdG include high-performance liquid chromatography, MS, and the enzyme-linked 
immunosorbent assay (101). 
Total Antioxidant Capacity 
 An organism’s antioxidant defense system may be temporarily abated as its components 





oxidative stress.  This measurement is performed by adding a known quantity of a given RONS 
to a sample and measuring the amount of RONS that is scavenged (102).  Measuring TAC serves 
as a better estimation of oxidative stress in vivo than measuring individual antioxidants 
separately, because TAC reflects the fact that antioxidants act synergistically to scavenge RONS 
(102).  Also, TAC is easier to perform and less costly than disentangling the antioxidants and 
examining each one separately (103).  Blood is the preferred biological fluid for TAC assays, 
because it is influenced by RONS overload and dietary antioxidant consumption, thus providing 
a more accurate representation of oxidative stress in vivo (102).  Several methods of assaying 
TAC are currently practiced, including Total Radical-Trapping Antioxidant Parameter, Ferric 
Reducing Ability of Plasma, Trolox Equivalent Antioxidant Capacity, and Oxygen Radical 
Absorbance Capacity.  Currently, none of these methods is considered to be the “gold standard” 
(103).  Moreover, “total antioxidant capacity” has been criticized as being a misnomer, because 
different methods of assaying TAC will yield different results due to the different reaction 
conditions (most notably, the species of RONS that is used) associated with each method (103).  
Thus, the emergence of a single method that can successfully determine total antioxidant 
capacity will likely never occur.  
Attenuating Oxidative Stress 
 Three main interventions can attenuate oxidative stress.  First, pharmacological 
interventions can reduce RONS formation.  Second, exercise can upregulate the endogenous 
antioxidant defense system.  Finally, antioxidant intake (either through diet or supplementation) 
and a reduction of dietary energy/dietary lipid can increase tissue antioxidant levels and lead to a 







 Several pharmaceuticals have been demonstrated to decrease RONS generation, 
including thiazolidinediones, statins, angiotensin type I (AT1) inhibitors, and angiotensin 
converting enzyme inhibitors.  Thiazolidinediones inhibit inducible nitric oxide synthase, an 
enzyme that diverts electrons from L-arginine to molecular oxygen to form O2
•-
 (104).  Statins, 
AT1 inhibitors, and angiotensin converting enzyme inhibitors reduce the activity of nicotinamide 
adenine dinucleotide phosphate oxidase, an enzyme responsible for increasing O2
•-
 production 
(105).  Nicotinamide adenine dinucleotide phosphate oxidase activity is stimulated when 
angiotensin II activates AT1 receptors.  Statins reduce AT1 receptor expression (106), AT1 
inhibitors prevent angiotensin II from activating AT1 receptors (107), and angiotensin converting 
enzyme inhibitors block the conversion of angiotensin I to angiotensin II (105).   
Exercise 
An exercise bout, whether aerobic or anaerobic, causes an acute elevation in RONS 
production, which can occur via multiple pathways: 1) increased oxygen consumption leads to 
increased cellular respiration, prostanoid metabolism, and/or autoxidation of catecholamines; and 
2) increased ischemia/reperfusion stimulates oxidase enzymatic activity (108).  Moreover, this 
initial elevation in RONS production can lead to subsequent elevations via proteolysis, 
inflammation, and/or a loss of balance in calcium homeostasis (108).  The amount of RONS 
elevation depends on a variety of factors, including: age, health, intensity and duration of 
exercise, training status, as well as the amount and duration of antioxidant 
intake/supplementation (108).   
Exercise-induced elevations in RONS formation cause an upregulation of the endogenous 





subsequent training sessions (109).  Specifically, exercise increases the activity of both 
antioxidant enzymes and oxidative damage repair systems (110).  Such an adaptation is 
consistent with the hormesis hypothesis, which proposes that repeated exposure to low-intensity 
stressors protects an organism from subsequent exposure to higher-intensity stressors (111).  
Two considerations are worthy of mention.  First, antioxidant supplementation may blunt the 
acute elevation in RONS that occurs during an exercise bout, thus removing the stimulus 
necessary for the upregulation of endogenous antioxidant defenses (112, 113).  Second, exercise 
of too high an intensity and/or too long a duration may lead to an exacerbated RONS elevation 
that inundates antioxidant defenses and contributes to poor health and disease (108).  Therefore, 
more research is needed to establish an “optimal” level of acute RONS elevation.  
Antioxidant Intake and Diet Modification 
 Exogenous antioxidants can be consumed via either diet or supplementation.  The 
exogenous antioxidants that have been most commonly researched are ascorbate (vitamin C), 
tocopherols (vitamin E), carotenoids, and flavonoids.  Once consumed, these antioxidants act 
synergistically to delay or inhibit oxidative damage (114, 115).    
 Vitamin C is regarded as one of the most potent and important antioxidants (114, 115).  




, and singlet oxygen 
(114).  Also, vitamin C has been demonstrated in vitro to regenerate vitamin E from the 
tocopheroxyl radical that is formed during the inhibition of lipid peroxidation (114).  It is 
recommended that 145 mg of vitamin C be consumed daily to reduce the risk of developing 
disease (114).  The main dietary sources of vitamin C are citrus fruits, kiwis, cherries, melons, 





 “Vitamin E” is a generic term for tocopherols and tocotrienols (115), which represent 4 
specific forms of tocopherols (alpha, beta, gamma, delta) and 4 specific forms of tocotrienols 
(alpha, beta, gamma, delta).  As an antioxidant, vitamin E mainly quenches lipid peroxyl radicals 
to produce lipid hydroperoxides and tocopheroxyl radicals (114).  The majority of tocopheroxyl 
radicals are then converted back to vitamin E via either vitamin C or glutathione (114).  Also, 
vitamin E has been shown to scavenge singlet oxygen and peroxynitrite (114).  It is 
recommended that 23 mg of vitamin E be consumed daily to reduce the risk of developing 
disease (114).  The main dietary sources of vitamin E are wheat germ, nuts, several green leafy 
vegetables, vegetable oils, and vegetable oil products (114).  Vitamin E and Vitamin C are 
currently the only two dietary antioxidants considered to meaningfully reduce oxidative damage 
in humans (116).                        
 Carotenoids are tetraterpenoid organic pigments that have the ability to dissolve fats, oils, 
and lipids.  These antioxidants are effective scavengers of singlet oxygen and peroxyl radicals 
(114).  Also, β-carotene, the most well-known carotenoid, is particularly effective at quenching 
trichloromethylperoxyl radicals (115).  It is recommended that 5.7 mg of carotenoids be 
consumed daily to reduce the risk of developing disease (114).  The main dietary sources of 
carotenoids are carrots (α-carotene and β-carotene) tomatoes (lycopene), citrus fruits (β-
cryptoxanthin), spinach (lutein), and corn (zeaxanthin) (114).           
 Flavonoids are polyphenolic compounds that exist in all plant families.  The main 
antioxidant subforms of flavonoids are flavones, flavanones, isoflavones, flavonols, flavononols, 
flavan-3-ols, and anthocyanidins (117).  Flavonoids inhibit xanthine oxidase and protein kinase 
C, which consequently lowers O2
•-
 production (117).  In addition, flavonoids chelate certain trace 





have a very poor bioavailability; in fact, only a few percent of ingested flavonoids are absorbed 
into the bloodstream (117).  Currently, little is known about the antioxidant effects of flavonoids 
in vivo, but it appears that these compounds may have a sparing effect on α-tocopherol and β-
carotene (117).  The main dietary sources of flavonoids are fruits, vegetables, seeds, nuts, grains, 
spices, tea, wine, and beer (117).        
 Aside from the above, many additional antioxidants are available within both whole 
foods and nutritional supplements.  Many nutritionists argue that the best method to ensure 
intake of a full spectrum of antioxidants is to consume a wide variety of fresh fruits, vegetables, 
and whole grains.  Such a dietary pattern is very low in saturated fat and cholesterol, is relatively 
low in total dietary energy, and likely results in a low and “healthy” production of RONS.  This 
plan is characteristic of the Daniel Fast.  
 
THE DANIEL FAST 
The Daniel Fast derives from two passages in the Book of Daniel.  In Daniel 1:8-14 
(NIV), Daniel asked the chief official for permission to consume nothing but vegetables and 
water for ten days.  This request was made in an effort to avoid the consumption of Babylonian 
food that was not prepared in accordance with the Mosaic Law.  Later in the same book (Daniel 
10:2-3 NIV), Daniel refrained from consuming choice food (meat or wine) for twenty-one days.  
Based on these two passages, a modern day Daniel Fast allows for ad libitum consumption of 
fruits, vegetables, whole grains, nuts, seeds, and oil.  Animal products, refined foods, white flour, 
preservatives, additives, sweeteners, flavorings, caffeine, and alcohol are each disallowed during 
this fast.  Thus, the Daniel Fast can be described as a variant of veganism and a form of DR.  





(ten-day) fasts have been observed.  Although no Biblical passage enjoins the faithful to observe 
the Daniel Fast at any particular time of the year, this fast is often partaken during the month of 
January to commemorate the New Year with fasting and prayer. 
 The only study to date that has examined the Daniel Fast reported favorable changes in 
cardiovascular health, glucoregulatory health, blood lipids, and oxidative stress (118, 119).  
Systolic BP, diastolic BP, TC, LDL-C, MDA, and H2O2 decreased during the fast.  Trolox 
Equivalent Antioxidant Capacity and nitrate/nitrite both increased from pre to post fast.  C-
reactive protein (3.15 ± 0.91 vs. 1.60 ± 0.42 mg L
-1
; p = 0.13), plasma insulin (4.42 ± 0.52 vs. 
3.37 ± 0.35 μU∙mL
-1
; p = 0.10), and the homeostatic model of insulin resistance (0.97 ± 0.13 vs. 
0.72 ± 0.08; p = 0.10) were each lowered to a clinically meaningful, albeit statistically 
insignificant, extent.  Plasma VLDL-C and TAG did not change significantly during the fast, nor 
did the TC:HDL-C ratio.  
 Some advantages may make the Daniel Fast a superior option to CR and ADF regimens 
for optimizing health.  The Daniel Fast’s allowance of ad libitum energy intake likely promotes 
greater satiety and compliance compared to dietary regimens that restrict energy consumption.  
Also, partaking in a Daniel Fast serves as an education in food choices, as nutrition labels must 
be checked to see if food selections comply with the fast’s restrictions (118). 
 Unfortunately, a notable drawback of the Daniel Fast appears to be its lowering of HDL-
C.  Indeed, this lipoprotein decreased by 14% in the lone investigation that examined the Daniel 
Fast (118).  This lowering of HDL-C was outpaced by a 19% reduction in TC, thus resulting in a 
reduced TC:HDL-C ratio (118).  However, given the important role of HDL-C in reverse 





 Theoretically, including an intervention known to raise HDL-C could counterbalance the 
lowering of this lipoprotein that occurs during the Daniel Fast.  Even though aerobic exercise is 
an excellent lifestyle intervention that should be performed by all able-bodied individuals, its 
minimal effect on HDL-C is likely insufficient to offset a fast-induced 14% reduction of this 
cholesterol.  Moreover, although several pharmaceuticals (statins, niacin, fibrates, 
thiazolidnediones, glitazars, CETP inhibitors, and HDL infusions) have been shown to 
substantially raise HDL-C, use of these drugs without a medical need departs from the 
abstemious philosophy of a Daniel Fast.  All-natural nutritional supplements, on the other hand, 
appear to be ideal intervention candidates.  Krill oil is particularly interesting in this regard, as 
one study reported a 43-60% increase in HDL-C following supplementation (67), while two 
recent studies (70, 71) reported no change in this cholesterol.  
Summary 
 Favorable changes in a multitude of health-related biomarkers were noted during the 
initial investigation of the Daniel Fast.  Such findings warrant a subsequent investigation 
designed to replicate (or improve on) the results of the initial study.  However, not every change 
noted in the initial investigation was desirable (e.g., a 14% reduction in HDL-C).  Therefore, a 
subsequent investigation should seek to maintain or improve HDL-C via an intervention that is 
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